Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ten More Class I Devices Would Require 510(k)s Under FDA Proposed Rule

This article was originally published in The Gray Sheet

Executive Summary

Ten additional Class I devices would be placed on FDA's "reserved" list of devices requiring a 510(k) submission under a proposed rule published in the Nov. 12 Federal Register.

You may also be interested in...



Premarket exemption final rule

Effective Feb. 14, rule lists all Class I and Class II devices that are exempted from premarket notification under the 1997 FDA Modernization Act. List includes cardiopulmonary bypass accessory equipment and electrode cables, devices which initially had been removed from the list following an FDA proposed rule reclassifying them to Class II and requiring them to meet certain performance standards (1"The Gray Sheet" Nov. 16, 1998, p. 10). The agency explains that as long as these devices met the standard there was no need for them to submit a 510(k), and clarified that this decision would have no effect on the proposed reclassification. On its own initiative, the agency also has added all versions of keratoscopes to the list; previously, keratoscopes using computer software were not considered exempt

Jefferies' Survey Predicts M&A Rebound In 2021

An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies. 

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel